25.25p-0.50 (-1.94%)17 Sep 2021, 17:05
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Genedrive PLC Fundamentals

Company NameGenedrive PLCLast Updated2021-09-17
IndustryDiagnostics & ResearchSectorHealthcare
Shares in Issue63.320 mMarket Cap£15.99 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.55EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0368Debt Equity Ratio0.0402
Asset Equity Ratio1.2807Cash Equity Ratio0.7118
Quick Ratio3.3081Current Ratio4.95
Price To Book Value3.0600ROCE0

Genedrive PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Genedrive PLC Company Financials

Tangible Assets£147,000.00£164,000.00£165,000.00
Intangible Assets000
Total Fixed Assets£194,000.00£317,000.00£505,000.00
Cash & Equivalents£8.22 m£5.18 m£3.53 m
Other Assets000
Total Assets£10.45 m£7.26 m£5.91 m
Creditors within 1 year£2.20 m£1.22 m£2.72 m
Creditors after 1 year£11.60 m£8.52 m£5.63 m
Other Liabilities000
Total Liabilities£13.79 m£9.73 m£8.35 m
Net assets-£3.34 m-£2.48 m-£2.44 m
Called up share capital£780,000.00£510,000.00£282,000.00
Share Premium£43.68 m£29.00 m£25.99 m
Profit / Loss-£20.38 m-£4.52 m-£7.79 m
Other Equity-£3.34 m-£2.48 m-£2.44 m
Preference & Minorities000
Total Capital Employed-£3.34 m-£2.48 m-£2.44 m
Debt Ratio000
Assets / Equity1.28071.28071.2807
Cash / Equity0.71180.71180.7118
Cash Flow202020192018
Cash from operating activities-£3.79 m-£3.62 m-£2.55 m
Cashflow before financing£3.08 m£1.69 m-£2.55 m
Increase in Cash£3.03 m£1.67 m-£1.60 m
Turnover£502,000.00£961,000.00£1.94 m
Cost of sales000
Gross Profit000
Operating Profit000
Pre-Tax profit-£20.38 m-£4.52 m-£7.79 m

Genedrive PLC Company Background

ActivitiesGenedrive PLC is a holding company engaged in molecular diagnostics business. It operates in one operating segment named as Diagnostics which is engaged in Genedrive Point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Geographically the majority of the revenue is derived from the United States of America.
Latest Interim Date25 Mar 2021
Latest Fiscal Year End Date17 Nov 2020

Genedrive PLC Directors

2018-04-09Ms. Catherine BoothExecutive Director,Managing Director - Contract Research Ser
2017-11-06Mr. Hugh John Joseph RylandsExecutive Director,Finance Director and Company Secretary
2011-11-10Mr. Gerard BradyExecutive Director,Research Director
2020-11-27Dr. Ian David GilhamNon-Executive Director,Chairman
2020-11-27Dr. Robert Dwyer NolanNon-Executive Director
2015-04-28Mr. David Eric EvansNon-Executive Director,Chairman
2016-11-11Mr. Matthew Heaton WallsExecutive Director
2013-11-26Mr. Jeffrey Gould MooreExecutive Director,Managing Director - Novel Therapies
2012-11-22Professor Christopher Stanislaus PottenExecutive Director,Chief Scientific Adviser
2020-11-27Dr. Roger LloydNon-Executive Director
2020-11-27Mr. Chris Henry Francis YatesNon-Executive Director
2017-11-08Dr. Allan BrownExecutive Director,Chief Operating Officer, Diagnostics
2020-11-27Mr. David BuddExecutive Director,Chief Executive Officer
2020-11-27Mr. Matthew John FowlerExecutive Director,Chief Financial Officer and Company Secretary
2020-11-27Mr. Thomas LindsayNon-Executive Director

Genedrive PLC Contact Details

Company NameGenedrive PLC
Address48 Grafton Street, The Incubator Building, Manchester, M13 9XX
Telephone+44 1619890245

Genedrive PLC Advisors

SolicitorCovington & Burling LLP
Phone+44 2070672000
Fax +44 2070672222
Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
StockbrokerPeel Hunt LLP
Phone+44 2074188900
BankNatwest Bank Plc
RegistrarNeville Registrars Ltd
Phone+44 1215851131
Fax+44 1215851132
Nominated AdviserPeel Hunt LLP
Phone+44 2074188900